Skip to main content
. 2019 Nov 11;63(2):266–277. doi: 10.1007/s00125-019-05016-3

Fig. 1.

Fig. 1

Violin plots of risk scores according to GAD65 antibody status for (a) type 1 diabetes and (b) type 2 diabetes in the EPIC-InterAct subcohort and incident diabetes cases. n values in (a) are: 12,526 (subcohort, GAD65Ab−), 149 (subcohort, low GAD65Ab+), 104 (subcohort, high GAD65Ab+), 9442 (incident diabetes, GAD65Ab−), 139 (incident diabetes, low GAD65Ab+), and 196 (incident diabetes, high GAD65Ab+). n values in (b) are: 12,249 (subcohort, GAD65Ab−), 146 (subcohort, low GAD65Ab+), 99 (subcohort, high GAD65Ab+), 9126 (incident diabetes, GAD65Ab−) and 135 (incident diabetes, low GAD65Ab+), 192 (incident diabetes, high GAD65Ab+). ‘High’ GAD65Ab+ is defined as GAD65 antibody ≥167.5 U/ml and ‘low’ GAD65Ab+ is defined as GAD65 antibody <167.5 U/ml. GAD65Ab+, GAD65 antibody positive; GAD65Ab−, GAD65 antibody negative; T1D, type 1 diabetes; T2D, type 2 diabetes